The therapeutic role of endothelial progenitor cells in Type 1 diabetes mellitus
2011 (English)In: Regenerative Medicine, ISSN 1746-0751, E-ISSN 1746-076X, Vol. 6, no 5, 599-605 p.Article, review/survey (Refereed) Published
Pancreatic beta-cells sense and adjust the blood glucose level by secretion of insulin. In Type 1 diabetes mellitus, these insulin-producing cells are destroyed, leaving the patients incapable of regulating blood glucose homeostasis. At the time of diagnosis, most patients still have 20-30% of their original beta-cell mass remaining. These residual beta-cells are targets for intervention therapies aimed at preventing further autoimmune destruction, in addition to increasing the number of existing beta-cells. Such a therapeutic option is highly desirable since it may lead to a full recovery of newly diagnosed patients, with no need for further treatment with immunosuppressant drugs or exogenous insulin administration. In this article, we propose that endothelial progenitor cells, a cell type known to promote and support neovascularization following endothelial injury, may be used as part of a combinational stem cell therapy aimed to improve the vascularization, survival and proliferation of beta-cells.
Place, publisher, year, edition, pages
2011. Vol. 6, no 5, 599-605 p.
beta-cells, endothelial cells, endothelial progenitor cells, stem cells, Type 1 diabetes
Physiology Immunology in the medical area
IdentifiersURN: urn:nbn:se:uu:diva-161309DOI: 10.2217/RME.11.45ISI: 000295786800013PubMedID: 21916595OAI: oai:DiVA.org:uu-161309DiVA: diva2:455688